☰

Inna Chervoneva, Ph.D. - Publications

Affiliations: 
2003 Temple University, Philadelphia, PA, United States 
Area:
Statistics
Tree Info Similar researchers PubMed Report error

40 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Yi M, Zhan T, Peck AR, Hooke JA, Kovatich AJ, Shriver CD, Hu H, Sun Y, Rui H, Chervoneva I. Selection of optimal quantile protein biomarkers based on cell-level immunohistochemistry data. Bmc Bioinformatics. 24: 298. PMID 37481512 DOI: 10.1186/s12859-023-05408-8  0.444
2023 Yi M, Zhan T, Peck AR, Hooke JA, Kovatich AJ, Shriver CD, Hu H, Sun Y, Rui H, Chervoneva I. Quantile Index Biomarkers Based on Single-Cell Expression Data. Laboratory Investigation; a Journal of Technical Methods and Pathology. 100158. PMID 37088463 DOI: 10.1016/j.labinv.2023.100158  0.497
2023 Chervoneva I, Peck AR, Sun Y, Yi M, Udhane SS, Langenheim JF, Girondo MA, Jorns JM, Chaudhary LN, Kamaraju S, Bergom C, Flister MJ, Hooke JA, Kovatich AJ, Shriver CD, et al. High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer. Jco Precision Oncology. 7: e2100498. PMID 36652667 DOI: 10.1200/PO.21.00498  0.406
2019 Hartsough EJ, Weiss MB, Heilman SA, Purwin TJ, Kugel CH, Rosenbaum SR, Erkes DA, Tiago M, HooKim K, Chervoneva I, Aplin AE. CADM1 is a TWIST1-regulated suppressor of invasion and survival. Cell Death & Disease. 10: 281. PMID 30911007 DOI: 10.1038/S41419-019-1515-3  0.321
2018 Ye Z, Wang C, Wan S, Mu Z, Zhang Z, Abu-Khalaf MM, Fellin FM, Silver DP, Neupane M, Jaslow RJ, Bhattacharya S, Tsangaris TN, Chervoneva I, Berger A, Austin L, et al. Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA. European Journal of Cancer (Oxford, England : 1990). 106: 133-143. PMID 30528798 DOI: 10.1016/J.Ejca.2018.10.012  0.317
2018 Tran TH, Utama FE, Sato T, Peck AR, Langenheim JF, Udhane SS, Sun Y, Liu C, Girondo MA, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Palazzo J, Bibbo M, ... ... Chervoneva I, et al. Loss of nuclear localized Parathyroid Hormone-related Protein in primary breast cancer predicts poor clinical outcome and correlates with suppressed Stat5 signaling. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30097435 DOI: 10.1158/1078-0432.Ccr-17-3280  0.512
2018 Chaudhary L, Peck A, Yunguang S, Hu H, Kovatich A, Hooke J, Shriver C, Mitchell E, Chervoneva I, Rui H. Abstract P4-09-06: High levels of Bruton's tyrosine kinase (BTK) protein is associated with favorable outcome in breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P4-09-06  0.35
2017 Morita Y, Zhang R, Leslie M, Adhikari S, Hasan N, Chervoneva I, Rui H, Tanaka T. Pathologic evaluation of tumor-associated macrophage density and vessel inflammation in invasive breast carcinomas. Oncology Letters. 14: 2111-2118. PMID 28789438 DOI: 10.3892/Ol.2017.6466  0.303
2017 Chervoneva I, Freydin B, Hyslop T, Waldman SA. Modeling qRT-PCR dynamics with application to cancer biomarker quantification. Statistical Methods in Medical Research. 962280216683204. PMID 28504051 DOI: 10.1177/0962280216683204  0.531
2017 Telonis AG, Magee R, Loher P, Chervoneva I, Londin E, Rigoutsos I. Knowledge about the presence or absence of miRNA isoforms (isomiRs) can successfully discriminate amongst 32 TCGA cancer types. Nucleic Acids Research. PMID 28206648 DOI: 10.1093/Nar/Gkx082  0.304
2016 Wang C, Mu Z, Chervoneva I, Austin L, Ye Z, Rossi G, Palazzo JP, Sun C, Abu-Khalaf M, Myers RE, Zhu Z, Ba Y, Li B, Hou L, Cristofanilli M, et al. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer. Breast Cancer Research and Treatment. PMID 27771841 DOI: 10.1007/S10549-016-4026-2  0.31
2016 Peck AR, Girondo MA, Liu C, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Mitchell EP, Freydin B, Hyslop T, Chervoneva I, Rui H. Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platforms. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 27312066 DOI: 10.1038/Modpathol.2016.112  0.497
2016 Teh JL, Purwin T, Greenawalt EJ, Chervoneva I, Goldberg A, Davies ME, Aplin A. Abstract 5199: An in vivo reporter to quantitatively and temporally analyze the effects of CDK4/6 inhibitor-based therapies in melanoma Cancer Research. 76: 5199-5199. DOI: 10.1158/1538-7445.Am2016-5199  0.303
2015 Capparelli C, Rosenbaum S, Berman-Booty LD, Salhi A, Gaborit N, Zhan T, Chervoneva I, Roszik J, Woodman SE, Davies MA, Setiady YY, Osman I, Yarden Y, Aplin AE. ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas. Cancer Research. 75: 3554-67. PMID 26206558 DOI: 10.1158/0008-5472.Can-14-2959  0.499
2015 Salem I, Aburto L, Addya S, Chervoneva I, Mu Z, Ruggeri B, Cristofanilli M, Fernandez SV. Abstract 3232: CEP-37440, a highly selective and potent dual inhibitor of ALK and FAK1 inhibits the proliferation of inflammatory breast cancer cells Cancer Research. 75: 3232-3232. DOI: 10.1158/1538-7445.Am2015-3232  0.333
2014 Lin J, Zhan T, Duffy D, Hoffman-Censits J, Kilpatrick D, Trabulsi EJ, Lallas CD, Chervoneva I, Limentani K, Kennedy B, Kessler S, Gomella L, Antonarakis ES, Carducci MA, Force T, et al. A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA. American Journal of Cancer Therapy and Pharmacology. 2: 21-32. PMID 25580468 DOI: 10.1200/Jco.2013.31.15_Suppl.5061  0.492
2014 Xu Y, Iglewicz B, Chervoneva I. Robust Estimation of the Parameters of g - and - h Distributions, with Applications to Outlier Detection. Computational Statistics & Data Analysis. 75: 66-80. PMID 24665144 DOI: 10.1016/J.Csda.2014.01.003  0.698
2014 Sato T, Tran TH, Peck AR, Girondo MA, Liu C, Goodman CR, Neilson LM, Freydin B, Chervoneva I, Hyslop T, Kovatich AJ, Hooke JA, Shriver CD, Fuchs SY, Rui H. Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression. Oncogene. 33: 2215-24. PMID 23708665 DOI: 10.1038/Onc.2013.172  0.523
2014 Chervoneva I, Vishnyakov M. Generalized S-estimators for linear mixed effects models Statistica Sinica. 24: 1257-1276. DOI: 10.5705/Ss.2012.285  0.315
2013 Yang N, Liu C, Peck AR, Girondo MA, Yanac AF, Tran TH, Utama FE, Tanaka T, Freydin B, Chervoneva I, Hyslop T, Kovatich AJ, Hooke JA, Shriver CD, Rui H. Prolactin-Stat5 signaling in breast cancer is potently disrupted by acidosis within the tumor microenvironment. Breast Cancer Research : Bcr. 15: R73. PMID 24004716 DOI: 10.1186/Bcr3467  0.518
2013 Ali M, Chervoneva I, Pitari GM. Abstract 3944: Serine phosphorylation of vasodilator-stimulated phosphoprotein regulates the tumorigenic potential of colon cancer cells. Cancer Research. 73: 3944-3944. DOI: 10.1158/1538-7445.Am2013-3944  0.304
2013 Girondo M, Peck A, Freydin B, Chervoneva I, Hyslop T, Kovatich A, Hooke J, Shriver C, Mitchell E, Rui H. Abstract P1-08-20: Increased risk of hormone therapy failure in breast cancers expressing low phospho-Stat5: Validation of quantitative immunofluorescence assay parameters Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P1-08-20  0.529
2012 Chervoneva I, Zhan T, Iglewicz B, Hauck WW, Birk DE. Two-stage hierarchical modeling for analysis of subpopulations in conditional distributions. Journal of Applied Statistics. 39: 445-460. PMID 22523443 DOI: 10.1080/02664763.2011.596193  0.709
2011 Chervoneva I, Vishnyakov M. Constrained S-estimators for linear mixed effects models with covariance components. Statistics in Medicine. 30: 1735-50. PMID 21638300 DOI: 10.1002/Sim.4169  0.308
2011 Showalter TN, Zhan T, Anne PR, Chervoneva I, Mitchell EP, Yeo CJ, Rosato EL, Kennedy EP, Berger AC. The influence of prognostic factors and adjuvant chemoradiation on survival after pancreaticoduodenectomy for ampullary carcinoma. Journal of Gastrointestinal Surgery : Official Journal of the Society For Surgery of the Alimentary Tract. 15: 1411-6. PMID 21523621 DOI: 10.1007/S11605-011-1518-6  0.519
2011 Holmes P, Lloyd J, Chervoneva I, Pequinot E, Cornfield DB, Schwartz GF, Allen KG, Palazzo JP. Prognostic markers and long-term outcomes in ductal carcinoma in situ of the breast treated with excision alone. Cancer. 117: 3650-7. PMID 21319154 DOI: 10.1002/Cncr.25942  0.31
2011 Behling KC, Tang A, Freydin B, Chervoneva I, Kadakia S, Schwartz GF, Rui H, Witkiewicz AK. Increased SIAH expression predicts ductal carcinoma in situ (DCIS) progression to invasive carcinoma. Breast Cancer Research and Treatment. 129: 717-24. PMID 21088888 DOI: 10.1007/S10549-010-1254-8  0.328
2011 Valicenti RK, Trabulsi E, Intenzo C, Lavarino J, Xu Y, Chervoneva I. A Phase I trial of samarium-153-lexidronam complex for treatment of clinically nonmetastatic high-risk prostate cancer: first report of a completed study. International Journal of Radiation Oncology, Biology, Physics. 79: 732-7. PMID 20399029 DOI: 10.1016/J.Ijrobp.2009.11.011  0.521
2010 Chervoneva I, Li Y, Schulz S, Croker S, Wilson C, Waldman SA, Hyslop T. Selection of optimal reference genes for normalization in quantitative RT-PCR. Bmc Bioinformatics. 11: 253. PMID 20470420 DOI: 10.1186/1471-2105-11-253  0.49
2010 Kline J, Chervoneva I, Freydin B, solomides C, Witkiewicz AK, Martin C, Peiper S. Insulin-like growth factor receptor 1(IGFIR) is overexpressed in a subset of triple negative breast cancers Clinical Cancer Research. 16. DOI: 10.1158/Diag-10-A29  0.321
2008 Zuzga DS, Gibbons AV, Li P, Lubbe WJ, Chervoneva I, Pitari GM. Overexpression of matrix metalloproteinase 9 in tumor epithelial cells correlates with colorectal cancer metastasis. Clinical and Translational Science. 1: 136-41. PMID 20443834 DOI: 10.1111/J.1752-8062.2008.00037.X  0.301
2007 Chervoneva I, Li Y, Iglewicz B, Waldman S, Hyslop T. Relative quantification based on logistic models for individual polymerase chain reactions. Statistics in Medicine. 26: 5596-611. PMID 17968873 DOI: 10.1002/Sim.3127  0.707
2007 Chervoneva I, Hyslop T, Hauck WW. A multivariate test for population bioequivalence. Statistics in Medicine. 26: 1208-23. PMID 16810712 DOI: 10.1002/Sim.2605  0.485
2006 Chervoneva I, Iglewicz B, Hyslop T. A general approach for two-stage analysis of multilevel clustered non-Gaussian data. Biometrics. 62: 752-9. PMID 16984317 DOI: 10.1111/J.1541-0420.2005.00512.X  0.703
2006 Chervoneva I, Hyslop T, Iglewicz B, Johns L, Wolfe HR, Schulz S, Leong E, Waldman S. Statistical algorithm for assuring similar efficiency in standards and samples for absolute quantification by real-time reverse transcription polymerase chain reaction. Analytical Biochemistry. 348: 198-208. PMID 16336939 DOI: 10.1016/J.Ab.2005.10.042  0.696
2006 Valicenti R, Trabulsi E, Intenzo C, Lavarino J, Xu Y, Chervoneva I. 2238 International Journal of Radiation Oncology*Biology*Physics. 66: S342. DOI: 10.1016/J.Ijrobp.2006.07.644  0.517
2005 Chervoneva I, Iglewicz B. Orthogonal bases approach for comparing nonnormal continuous distributions Biometrika. 92: 679-690. DOI: 10.1093/Biomet/92.3.679  0.656
2004 Cornfield DB, Palazzo JP, Schwartz GF, Goonewardene SA, Kovatich AJ, Chervoneva I, Hyslop T, Schwarting R. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cancer. 100: 2317-27. PMID 15160334 DOI: 10.1002/Cncr.20260  0.506
2003 Ober C, Aldrich CL, Chervoneva I, Billstrand C, Rahimov F, Gray HL, Hyslop T. Variation in the HLA-G promoter region influences miscarriage rates. American Journal of Human Genetics. 72: 1425-35. PMID 12721954 DOI: 10.1086/375501  0.46
2002 Berghella V, Haas S, Chervoneva I, Hyslop T. Patients with prior second-trimester loss: prophylactic cerclage or serial transvaginal sonograms? American Journal of Obstetrics and Gynecology. 187: 747-51. PMID 12237658 DOI: 10.1067/Mob.2002.124289  0.465
Show low-probability matches.